Showing 4261-4270 of 5771 results for "".
- CooperVision Introduces 2021 Best Practices Honoreeshttps://modernod.com/news/coopervision-introduces-2021-best-practices-honorees/2478943/During a year of unprecedented challenges brought on by the COVID-19 pandemic, eye care practices across the nation have adapted to meet the changing needs of their patients and find ways to not only survive, but thrive. In celebration of 10 such practices, CooperVision announced its 2021 Bes
- Second Sight Receives FDA Approval for the Argus 2s Retinal Prosthesis Systemhttps://modernod.com/news/second-sight-receives-fda-approval-for-the-argus-2s-retinal-prosthesis-system/2478941/Second Sight Medical Products announced FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). Th
- Sight Sciences Receives FDA Clearance for Expanded Indication for OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-receives-fda-clearance-for-expanded-indication-for-omni-surgical-system/2478938/Sight Sciences announced FDA 510(k) clearance of the OMNI Surgical System for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy to reduce IOP in adult patients with primary open–angle glaucoma. Historically, the majority o
- Hydrus Microstent Now First MIGS Device With 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/Ivantis, developer of the novel Hydrus Microstent, announced the first release of 5-year follow-up data from its HORIZON pivotal trial. This milestone represents the longest continuous follow-up of a MIGS device pivotal trial. The 5-year HORIZON data demonstrated the Hydrus Microstent̵
- Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trialhttps://modernod.com/news/nicoxs-ncx-470-receives-approval-by-chinese-authorities-for-local-start-of-denali-phase-3-trial/2478936/Nicox SA announced that its partner, Ocumension Therapeutics, has received approval from China’s Center for Drug Evaluation of the National Medical Products Administration to conduct
- Retina Consultants of America Continues Growth With Partnership in Kansas and Missourihttps://modernod.com/news/retina-consultants-of-america-continues-growth-with-partnership-in-kansas-and-missouri/2478935/Retina Consultants of America (RCA) announced it has added Retina Associates, P.A. of Kansas City, based in Kansas and Missouri, to its group of practices. Retina Associates, P.A. serves the greater Kansas City, Topeka, Sedalia, and surrounding areas. Terms of the deal were no
- PYC’s Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Modelshttps://modernod.com/news/pycs-lead-investigational-drug-vp-001-demonstrates-another-key-functional-improvement-in-patient-derived-models/2478930/PYC Therapeutics announced that the company’s lead investigational drug, VP-001, for the treatment of RP11 has restored function of the retinal pigment epithelium (RPE), the target cells for the therapy, in patient-derived models of the disease. “This result builds further conviction in VP
- Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-patient-dosing-in-first-cohort-of-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478927/Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicenter,
- FDA Accepts Oyster Point’s Filing of NDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/fda-accepts-oyster-points-filing-new-drug-application-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478928/Oyster Point Pharma announced that the FDA has accepted its new drug application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The Prescription Drug User Fee Act (PDUFA) target action date for OC-01 (varenicline) nasal spray is October 17, 2
- Bio-Tissue Receives FDA Clearance to Proceed with Clinical Study Using Investigational New Drug TTBT01https://modernod.com/news/bio-tissue-receives-fda-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-ttbt01/2478924/Bio-Tissue announced that its parent company TissueTech had received clearance from the FDA to proceed with a phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) investigational new drug (IND) TTBT01. This clearance represents another milest